Avadel Q1 2020 Earnings Report
Key Takeaways
Avadel Pharmaceuticals reported first quarter 2020 financial results, with revenues of $12.2 million compared to $16.4 million in the first quarter of 2019. The company's net loss for the quarter was $0.9 million, or $0.02 per share, compared to a net loss of $13.0 million, or $0.35 per share, for the same period in 2019.
Revenues for the first quarter of 2020 were $12.2 million, compared to $16.4 million in the first quarter of 2019.
R&D expenses were $5.5 million in the first quarter of 2020, compared to $7.3 million in the first quarter of 2019.
SG&A expenses were $7.9 million in the first quarter of 2020, compared to $10.4 million in the first quarter of 2019.
Net loss for the first quarter of 2020 was $0.9 million, or $0.02 per share, compared to a net loss of $13.0 million, or $0.35 per share, for the same period in 2019.
Avadel
Avadel
Forward Guidance
Avadel is focused on finalizing the New Drug Application (NDA), compiling additional supporting scientific data to position FT218 in the market and expanding capabilities to prepare for product launch.